疹简单病毒 bronchopneumonitis 在急性或慢性肝衰竭的重症患者:一个回顾性分析
Miriam Dibos1, Julian Triebelhorn1, Jochen Schneider1
1Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, Ismaninger Str. 22, 81675 Munich, Germany.
Viruses
|March 28, 2024
概括
在患有急性慢性肝衰竭 (ACLF) 的重症患者中,单纯疹病毒-1 (HSV) 的重新激活并没有增加死亡率. 然而,它导致了更长的机械通风和更多的真菌超级感染.
科学领域:
- 临界护理医学 临界护理医学
- 肝病学 肝病学是一种肝病学.
- 传染性疾病 传染性疾病
背景情况:
- 肺部简单疹病毒-1 (HSV) 的重新激活在重症患者中很常见,可能导致支气管肺炎和增加死亡率.
- 在患有急性慢性肝衰竭 (ACLF) 的患者中,HSV重新激活的影响仍然未知.
研究的目的:
- 调查HSV再激活对患有ACLF的重症患者的影响.
主要方法:
- 从2016年1月到2023年8月对136名机械通风ACLF患者的回顾性分析.
- 在患有和没有HSV支气管炎的患者之间比较临床参数.
主要成果:
- 10.3%的患者被诊断出患有HSV支气管肺炎.
- 死亡率在各组之间是相似的 (85.7%与75.4%,p=0.52).
- HSV组经历了更长的机械通风 (21 vs. 14天,p=0.04) 和更多的真菌超级感染 (28.6% vs. 6.6%,p=0.006).
结论:
- 尽管肝硬化相关的免疫功能障碍,但HSV支气管炎并没有增加严重病情的ACLF患者的死亡率.
- HSV的重新激活使临床过程复杂化,需要更长的机械通风.
相关概念视频
Acute Respiratory Failure-V
137
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
137
Acute Respiratory Failure-III
184
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
184
Acute Respiratory Failure-II
222
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
222
Acute Respiratory Failure-I
204
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
204
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
Pneumonia IV: Management
324
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
324


